Loading...
Loading...
Getting deals done in biopharmaceutical industry has been tough over the last few months but today FTSE 100-listed giant GlaxoSmithKline announced the $2 billion acquisition of Boston Pharmaceutical's lead asset, efimosfermin alfa.